Aspects of Lipid-Lowering Therapy With Atorvastatin in Patients With Myocardial Infarction From the Perspective of Personalized Medicine

Солодун, М. В.; Yаkushin, S. S.

doi:10.20996/1819-6446-2015-11-1-31-35

Cited by 4 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moscow / Москва *¹ [65] Moscow / Москва *² [66] Moscow / Москва [67] Moscow / Москва ³ [68] Laks / Лакцы [22] Dargins / Даргинцы [22] Avars / Аварцы [22] Russians / Русские 4 [69] Nanais / Нанайцы [23] Population / Популяция Prevalence / Распространенность (%) Figure 8. Ryazan / Рязань *¹ [72] Yaroslavl / Ярославль *² [73] Nanais / Нанайцы [23] Russians / Русские ³ [74] Avars / Аварцы [22] Yakuts / Якуты [20] Yakuts / Якуты 4 [74] Dargins / Даргинцы [22] Laks / Лакцы [22] Population / Популяция Prevalence / Распространенность (%) Figure 9. A. Rozhkov и соавт.…”

Section: Ihd / ибс [24]unclassified

See 1 more Smart Citation

Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population

Мирзаев

Fedorinov

Ivashchenko

et al. 2019

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Aim. To summarize Russian studies using pharmacogenetic testing as applied to cardiology.Material and methods. The authors conducted an online search for articles in December 2018 using the following databases: PubMed, Google Scholar, eLIBRARY. The search was carried out by keywords: "Russia", "Russian", "cardiology" together with the terms associated with the polymorphic marker, including: «P450», «CYP2C19», «CYP2D6», «CYP2B1», «CYP2B6», «CYP2Е1», «CYP2C8», «CYP2C9», «CYP3A4», «CYP3A5», «CYP1A1», «CYP1A2», «CYP4F2», «CYP4F1», «ABCB1», «SLCO1B1», «VKORC1», «GGCX», «SULT1A1», «CULT1», «CES1», «gene», «genes», «pharmacogenetics», «pharmacogenomics», «ethnic group».Results. Generalization of information allowed to identify obscure genes that need to be investigated in pharmacogenetic studies. This information can be used for the development of dosing algorithms and the priority choice of drugs, considering the results of pharmacogenetic testing and planning future research.Conclusion. The results of the literature review indicate the importance of studying the most clinically valid and clinically useful pharmacogenetic markers (CYP2C19, CYP2C9, VKORC1, SLCO1B1) among various ethnic groups in the Russian Federation. With the accumulation of evidence of clinical validity and clinical utility of other pharmacogenetic markers (CES1, CYP2D6*4, etc.), the problem of interethnic differences in the carriage of clinically significant polymorphisms of these genes identified in previous studies in the Russian Federation increasingly requires attention. The most promising for the introduction into the clinical practice in the Russian Federation in the near future are polymorphic markers of the CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes.

show abstract

Section: Ihd / ибс [24]unclassified

“…М. Солодун и соавт. обнаружили статистически значимое уменьшение атерогенных фракций холестерина у носителей SLCO1B1*5 аллели при приеме аторвастатина [74].…”

Section: Slco1b1unclassified

Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population

Мирзаев

Fedorinov

Ivashchenko

et al. 2019

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

show abstract

“…По нашим данным, не выявлено значимого влия-ния полиморфизма генов SLCO1B1*5 и LIPC (C514T) на 3-месячный прогноз после перенесенного ИМ [15]. Однако наше исследование было ограничено небольшим количеством респондентов и краткосроч-ностью наблюдения.…”

Section: фармакотерапия при инфаркте миокарда: вклад генетических факunclassified

Conservative Therapy in Myocardial Infarction: The Impact of Genetic Factors

Солодун¹

2016

Russ J Cardiol

Self Cite

View full text Add to dashboard Cite

Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy

Rumyantsev

Кукес

Казаков

et al. 2017

Terapevticheskii arkhiv

View full text Add to dashboard Cite

The number of patients receiving statins increases every year and due to the fact that they should take statins during their lives, the problem of their safety use comes to the forefront. The paper analyzes the safety of using the medications of this group and discusses the diagnosis of myopathies induced by statins and the occurrence of immune-mediated statin myopathies. It considers a personalized approach to prescribing statins, analyzes Russian and foreign experience in using pharmacogenetics to reduce the risk of myopathies, publishes the results of the authors' experience in clinically introducing pharmacogenetic testing at hospitals, and analyzes the long-term results of determining the polymorphism of the SLCO1B1 gene for the prediction of the risk of adverse events when using statins and estimating patient compliance to prescribed treatment.

show abstract

Aspects of Lipid-Lowering Therapy With Atorvastatin in Patients With Myocardial Infarction From the Perspective of Personalized Medicine

Cited by 4 publications

References 9 publications

Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population

Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population

Conservative Therapy in Myocardial Infarction: The Impact of Genetic Factors

Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy

Contact Info

Product

Resources

About